JASMA

Editor’s note: The requested title uses the spelling “Reccomends” and “Semiglutide.” In the article below, the standard spellings “recommends” and “semaglutide” are used where appropriate for clarity, accuracy, and SEO performance.

The weight-loss world has been moving fast enough to make a treadmill feel jealous. GLP-1 medications, telehealth clinics, compounded alternatives, direct-to-consumer ads, social media testimonials, and “lose weight without thinking about it” promises have all collided in one giant marketing smoothie. Into that crowded room walked the National Advertising Division, better known as NAD, with a very clear message for Willow Health: health claims need real proof, not just optimistic wording and a friendly checkout button.

On December 4, 2025, BBB National Programs’ National Advertising Division recommended that Willow Health Services, Inc. modify or discontinue certain health-related claims for its compounded semaglutide products. The case followed a challenge brought by Novo Nordisk, the pharmaceutical company behind FDA-approved semaglutide medicines such as Ozempic, Wegovy, and Rybelsus. At the center of the dispute was a simple but important question: can a telehealth company use studies about FDA-approved semaglutide products to support claims about its own compounded semaglutide offerings?

NAD’s answer was basically: not so fast.

What Happened in the Willow Health NAD Case?

Willow Health is a telehealth company that markets GLP-1 medications, including compounded semaglutide products. According to the NAD decision summary, Willow’s product line included “Semaglutide Tablets” and “Semaglutide Plus,” an injectable compounded semaglutide product. Novo Nordisk challenged Willow Health’s express and implied advertising claims related to weight loss, health benefits, safety, efficacy, and product superiority.

In plain English, Novo Nordisk argued that Willow’s advertising could lead consumers to believe its compounded semaglutide products had proven benefits comparable to FDA-approved semaglutide medications. Willow defended its advertising by pointing to prescribing decisions made by individual doctors and to disclosures stating that its products had not gone through clinical trials assessing safety or effectiveness.

NAD was not persuaded. The division concluded that Willow did not provide enough evidence to support the challenged claims. It also found that studies involving Novo Nordisk’s FDA-approved semaglutide products were not enough to validate claims for compounded alternatives that may differ in active pharmaceutical ingredient, formulation, dosage form, or method of administration.

That distinction matters. A compounded product is not automatically the same as an FDA-approved drug just because both are associated with the word “semaglutide.” In advertising law, close enough is not a scientific standard. It is what happens when someone eyeballs a recipe and accidentally makes soup instead of pasta sauce.

Why NAD Recommended Discontinuing or Modifying the Claims

NAD’s recommendation focused on substantiation. Health-related advertising claims require a reasonable basis before they are made. For serious medical or weight-loss claims, that usually means competent and reliable scientific evidence, not vibes, assumptions, or a few enthusiastic before-and-after stories.

Willow Health’s argument that physician involvement substantiated the claims did not carry the day. A doctor’s prescribing decision may be important for patient care, but NAD viewed it as insufficient to prove broad advertising claims about a product’s safety, effectiveness, or superiority. A clinician can evaluate an individual patient; that does not automatically create clinical proof that a marketed product performs as advertised for consumers generally.

NAD also took issue with relying on research about FDA-approved semaglutide drugs to support claims about compounded versions. FDA-approved products are reviewed for safety, effectiveness, manufacturing quality, labeling, dosage, and intended use. Compounded drugs, by contrast, are made for specific patient needs and are not FDA-approved before marketing. That difference is not a tiny footnote. It is the whole plot.

Because Willow did not provide evidence that directly supported the challenged claims for its own compounded products, NAD recommended that the company discontinue or modify the advertising to avoid communicating unsupported messages.

What Does “Compounded Semaglutide” Mean?

Compounded semaglutide refers to a medication prepared by a compounding pharmacy or outsourcing facility rather than manufactured as an FDA-approved branded drug. Compounding can be legitimate in specific situations, such as when a patient needs a customized dosage form or when an approved drug is unavailable during a shortage. However, compounded drugs are not reviewed by the FDA for safety, effectiveness, or quality before they are sold.

This is where consumers can get confused. If an online clinic says a product contains semaglutide, many people assume it is equivalent to Ozempic or Wegovy. That assumption can be risky. FDA-approved semaglutide products have specific labels, dosage schedules, warnings, manufacturing controls, and clinical trial data behind them. Compounded versions may differ in formulation, ingredients, concentration, delivery method, and pharmacy practices.

Some compounded semaglutide products have also raised concerns because of dosing errors, salt forms, unclear sourcing, and marketing language that suggests equivalence with approved medications. The FDA has warned that compounded drugs are not generics. A generic drug is FDA-approved; a compounded drug is not. That difference should be clear in advertising, especially when people are making decisions about prescription weight-loss medication.

Why the Semaglutide Shortage Changed the Market

The rise of compounded GLP-1 medications did not happen in a vacuum. Demand for GLP-1 drugs exploded as more people sought treatment for obesity, weight management, and type 2 diabetes. During shortages, compounding pharmacies had more room under federal law to prepare versions of certain medications when patient access was limited.

But the FDA determined in February 2025 that the shortage of semaglutide injection products had been resolved. That changed the compliance landscape. Once a drug is no longer on the shortage list, mass compounding of products that are essentially copies of FDA-approved drugs faces greater legal and regulatory risk. The FDA gave certain compounders transition periods, but the broader message was unmistakable: shortage-based flexibility is not a permanent business model.

For telehealth companies and online weight-loss brands, that created a marketing squeeze. Many had built consumer demand around lower-cost or easier-access GLP-1 options. But as regulatory scrutiny increased, claims that once seemed bold and clickable started looking legally fragile.

What Makes Weight-Loss Advertising So Sensitive?

Weight-loss advertising has always been a high-risk category because it targets a deeply personal concern. People searching for help with weight management may be frustrated, embarrassed, hopeful, or tired of being told to “just eat less” by people who have never met a midnight refrigerator. That emotional context makes accuracy especially important.

Claims such as “clinically proven,” “safe,” “effective,” “personalized,” “doctor-backed,” or “same active ingredient” can strongly influence consumer decisions. If those claims are not properly qualified, they may imply more certainty than the advertiser can prove. In the GLP-1 space, even small wording choices can create big impressions.

For example, saying a compounded product contains the “same active ingredient” as an FDA-approved drug may suggest sameness in safety and effectiveness. Saying patients can lose “up to 20%” of body weight may imply results from clinical trials apply directly to the advertised product. Saying a treatment is “doctor prescribed” may reassure consumers, but it does not prove that the advertised claims are supported by product-specific clinical evidence.

NAD Is Not the FDA, But Its Decisions Matter

NAD is part of BBB National Programs and operates as an advertising self-regulatory forum. It is not a government agency. However, its decisions matter because many advertisers comply voluntarily, and noncompliance can lead to referrals to government regulators or advertising platforms.

In the Willow Health case, NAD noted that Willow did not provide an advertiser statement confirming that it would comply with the recommendations. Willow maintained that its challenged advertising was truthful and could be substantiated. As a result, NAD said it would refer the matter to appropriate regulatory authorities and relevant platforms.

That does not mean Willow was found liable by a court, and it does not mean every Willow customer had a negative experience. It means NAD reviewed the advertising claims and found the substantiation inadequate under advertising standards. For marketers, that is a loud bell. For consumers, it is a reminder to read health claims with both eyes open.

What Consumers Should Take Away

If you are considering semaglutide, tirzepatide, or any GLP-1 medication through an online clinic, the Willow Health NAD decision offers several practical lessons.

1. Ask whether the product is FDA-approved

Do not assume a medication is FDA-approved because the website looks polished or the checkout process feels medical. Ask directly whether the exact product being prescribed is FDA-approved, compounded, or something else.

2. Look for clear risk information

GLP-1 medications can have side effects, including nausea, vomiting, diarrhea, constipation, abdominal pain, gallbladder issues, pancreatitis warnings, kidney-related concerns, and other risks depending on the product and patient. Advertising that talks only about effortless weight loss and skips meaningful safety information should raise eyebrows.

3. Be cautious with “clinically proven” language

Clinical studies about one product do not automatically prove claims about another product. The relevant question is whether the advertised product itself has evidence behind the claim.

4. Check the pharmacy and prescriber details

A legitimate treatment process should involve appropriate medical screening, clear prescription information, identifiable pharmacy involvement, follow-up care, and transparent safety instructions. If the buying process feels more like ordering sneakers than receiving prescription medication, slow down.

What Marketers Can Learn From the Willow Health Decision

For healthcare marketers, this case is a neat little compliance seminar wrapped in a GLP-1 headline. The lesson is not “never advertise compounded medications.” The lesson is that every claim must be supported, qualified, and tied to the actual product being sold.

Marketers should avoid borrowing clinical trial results from FDA-approved drugs unless the connection is accurate, limited, and carefully explained. They should not imply FDA approval where none exists. They should not use patient testimonials to communicate results that are not typical or scientifically supported. They should not rely on disclosures to fix a headline that makes an unsupported promise. A tiny disclaimer cannot always rescue a giant claim wearing tap shoes.

Healthcare brands should also review implied claims. A page may never explicitly say “our compounded product is just as safe as Wegovy,” but the combination of layout, wording, testimonials, photos, physician imagery, and pricing comparisons could still communicate that message. Regulators and self-regulatory bodies look at the net impression, not just isolated words.

Why This Case Fits a Bigger GLP-1 Advertising Crackdown

The Willow Health decision is part of a broader wave of scrutiny around compounded GLP-1 drugs. The FDA has warned telehealth companies about marketing that suggests compounded products are equivalent to FDA-approved drugs. It has also raised concerns about dosing errors, adverse events, salt forms of semaglutide, counterfeit products, and illegally marketed online drugs.

The FTC’s health advertising framework points in the same direction: objective health claims must be truthful, not misleading, and supported before they are made. Weight-loss promises are not exempt from that standard just because the website has pastel colors and a smiling doctor stock photo.

As GLP-1 medications remain popular, companies will keep competing for attention. Some will emphasize affordability. Some will emphasize convenience. Some will emphasize personalized care. Those themes can be legitimate, but they cannot replace evidence. In healthcare advertising, “easy” is not the same as “proven,” and “popular” is not the same as “safe.”

Experience-Based Lessons: What This Topic Feels Like in the Real World

For consumers, the experience of shopping for GLP-1 treatment online can feel both empowering and overwhelming. On one hand, telehealth can make medical care more accessible. A person who has struggled for years with weight management may finally find a clinician who listens, a treatment plan that feels realistic, and a platform that removes some of the friction from getting help. That matters. Access is not a minor issue; it is often the difference between starting care and giving up.

On the other hand, the online weight-loss marketplace can be confusing. A consumer may see phrases like “doctor prescribed,” “customized GLP-1,” “same active ingredient,” “clinical results,” and “simple monthly plan” and reasonably believe the product is basically the same as a well-known FDA-approved medication. The checkout page may be smooth, the branding may be calming, and the testimonials may be inspiring. But none of that answers the core questions: What exactly is in the medication? Who made it? Is it FDA-approved? What evidence supports the claims? What risks apply to this specific product?

From a patient-experience perspective, trust is built in the details. A trustworthy platform should make important information easy to find, not hide it behind cheerful marketing. It should explain whether a drug is compounded, what that means, where it is dispensed, what side effects to watch for, and how follow-up care works. It should help patients understand realistic expectations instead of dangling dramatic weight-loss numbers like a carnival prize.

For content creators and SEO publishers, this topic also shows why medical-adjacent writing requires extra care. Articles about semaglutide, compounded GLP-1 drugs, or telehealth weight-loss services should not treat advertising claims as proven facts. A headline may be tempting, but accuracy is the oxygen mask. Writers should distinguish between FDA-approved medications and compounded alternatives, between clinical trial results and marketing claims, and between a regulatory recommendation and a court judgment.

For marketers inside healthcare companies, the Willow Health case is a practical reminder to pressure-test every claim before launch. Ask: What does this sentence imply? Would a reasonable consumer think we are promising a specific result? Are we using research from another product to support our own? Is our disclosure clear enough, close enough, and strong enough? Would the claim still make sense if a regulator read it slowly with coffee and a red pen?

The most useful experience lesson is simple: people do not want perfect advertising; they want honest advertising. They want to know what a treatment may do, what it may not do, and what risks they should discuss with a qualified clinician. In a market as emotionally charged as weight loss, that honesty is not just a compliance obligation. It is a competitive advantage.

Conclusion

The NAD recommendation involving Willow Health and compounded semaglutide claims is more than a niche advertising dispute. It is a snapshot of a fast-changing healthcare marketplace where consumer demand, telehealth convenience, drug shortages, compounding practices, and regulatory scrutiny all meet at the same intersection.

The big lesson is straightforward: health claims need evidence that matches the product being advertised. Studies on FDA-approved semaglutide drugs cannot automatically support claims for compounded alternatives. Physician involvement is important for care, but it does not replace claim substantiation. Disclosures help, but they cannot cure every misleading impression.

For consumers, the safest approach is to ask direct questions, read beyond the headline, and discuss GLP-1 treatment options with a licensed healthcare professional. For advertisers, the message is even simpler: do not let your marketing write checks your evidence cannot cash.